Lindilane

Quick links to important sections

Lindilane

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lindilane

Quick Facts

Property Description
Active ingredients Acetaminophen, Codeine
Common form Tablet or Capsule
Pharmacological class Combination Analgesic (Opioid/Non-opioid)
Origin Synthetic (Acetaminophen) and Semi-synthetic (Codeine)

What Type of Medicine is Lindilane?

Lindilane is a proprietary medicinal product classified as a combination analgesic, containing two distinct active substances designed to relieve discomfort. This structure functionally places it in the category of medicines that pair a non-opioid component with an opioid agent, offering a more comprehensive approach to pain management than single-ingredient formulas. The underlying Acetaminophen and Codeine combination is recognized within clinical frameworks for pain relief for its consistent efficacy. This grouping signifies that the medicine is established and recognized for use in temporary discomfort relief.


Lindilane’s Dual-Component Composition

The specific active ingredients in Lindilane are Acetaminophen (Paracetamol) and Codeine. Acetaminophen is a well-known synthetic analgesic, while Codeine is semi-synthetic, derived from a naturally occurring opium alkaloid. Lindilane is typically manufactured for oral administration as a tablet or capsule. Clinical analysis of the fixed combination of these components has noted its effectiveness in providing relief for acute discomfort. This verification supports the use of the combination to help ease short-term physical distress.


The General Purpose of Lindilane

The core therapeutic purpose of Lindilane is to provide enhanced pain management through a dual-action mechanism. This involves Acetaminophen acting centrally to diminish the perception of pain and moderate fever, while Codeine works on the central nervous system to lessen the sensation and emotional impact of the pain itself. Lindilane is commonly utilized for the temporary relief of discomfort following minor procedures or injuries. The identity of this combination analgesic is defined by its ability to modulate the body's pain signaling effectively, delivering efficient, temporary symptomatic relief for acute physical distress.

What side effects are possible with Lindilane?

Possible Side Effects and Safety Information

The safety profile of Lindilane is formally documented by regulatory authorities, with adverse reactions classified by frequency and affected body system. These classifications focus on the spectrum of possible effects across body systems.


Frequency-Classified Adverse Reactions

Adverse effects commonly reported in official labeling frequently involve the Nervous System and the Gastrointestinal System. Common effects include drowsiness, lightheadedness, dizziness, sedation, nausea, vomiting, and constipation. Less commonly reported effects include conditions such as euphoria, dysphoria, and pruritus (itching).


Serious Adverse Reactions and Systemic Risks

Regulatory documents identify specific serious adverse reactions. These include the potential for Life-Threatening Respiratory Depression and severe Hepatic Necrosis, which is primarily associated with the acetaminophen component. Additionally, severe skin reactions, such as Stevens-Johnson Syndrome, are officially documented systemic risks.


Population and Contextual Safety Constraints

The safety profile includes restrictions for specific patient populations. The medicine is contraindicated in children less than 12 years of age and in adolescents under 18 following tonsillectomy or adenoidectomy. It is also not recommended for use by breastfeeding women due to the potential for serious adverse effects in the infant. A major constraint applies to individuals identified as CYP2D6 ultra-rapid metabolizers due to increased risks. Furthermore, official labeling notes that the risk of respiratory depression may be highest during the initiation of therapy or following a dose increase. Repeated administration may also lead to the development of physical dependence and tolerance.

Overdose and Emergency Response

Overdose of this combination analgesic involves two distinct, potentially life-threatening toxicities: acute liver failure from the Acetaminophen component and life-threatening respiratory and CNS depression from the Codeine component.

Regulatory bodies mandate that individuals seek immediate medical attention for suspected overdose, even if symptoms are absent, due to the risk of delayed, severe hepatic injury. Urgent medical help is also required immediately upon recognition of signs of breathing difficulty, such as slow or shallow respiration, which affects the Respiratory System. Other documented presentations related to the opioid component include confusion, extreme drowsiness, loss of consciousness, and small pupils (miosis).

The official overdose protocol requires the administration of two specific antidotes: Naloxone to reverse the opioid effects and N-acetylcysteine (NAC) to mitigate the Acetaminophen toxicity. Required monitoring is mandatory, including continuous assessment of vital signs and specialized laboratory tests, such as liver function tests and serum Acetaminophen concentration assays.

Population-specific warnings note the risk of fatal Codeine overdose from accidental ingestion of even a single dose by children. Increased risk of severe outcomes is also officially noted for patients with pre-existing hepatic or renal impairment.

Therapeutic Uses of Lindilane

What Lindilane Treats: Main Uses and Benefits

Lindilane is generally used to provide supportive symptomatic relief, particularly for symptoms related to physical discomfort and systemic imbalance. This combination is applied across domains where additional symptomatic support is needed.

The medication helps address symptom clusters that may become intense or disruptive, such as moderate and acute pain and febrile symptoms (fever) that occur together in certain acute conditions. It is commonly used across conditions presenting with acute episodes like managing discomfort following minor surgical procedures, acute dental procedures, or pain resulting from minor injuries (post-traumatic scenarios).

Key Use: Symptomatic Relief for Acute Discomfort

  • Primary Focus: Moderate to Acute Pain
  • Secondary Focus: Associated Febrile Symptoms

This approach supports general comfort during periods of heightened symptoms. It assists with maintaining functional stability when symptoms interfere with routine activities, and may help patients cope more steadily with difficult episodes.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Lindilane’s official eligibility profile is strictly defined by regulatory documents, establishing clear limitations based on age, metabolic status, and underlying health conditions.

Absolute Contraindications

Use is strictly prohibited for children younger than 12 years of age, women who are breastfeeding, and individuals identified as CYP2D6 ultra-rapid metabolizers. The medicine is also contraindicated in all pediatric patients following tonsillectomy and/or adenoidectomy for obstructive sleep apnoea.

Conditional and Restricted Use

Adults are the standard eligible population. Adolescents (12-18 years) may use the medicine conditionally; however, use is generally not recommended for adolescents with compromised respiratory function. Pregnant women are advised to avoid the medicine, especially regular use.

Cautionary Populations

Caution is required for patients with pre-existing conditions affecting organ function, including severe hepatic impairment or severe renal impairment. Other cautionary populations noted in regulatory labeling include the elderly and patients with a history of substance dependence or conditions like increased intracranial pressure.

What should I know about interactions with other medicines?

Lindilane’s interaction profile is formally defined in regulatory documents based on two critical patterns: metabolic enzyme modulation and pharmacodynamic reinforcement. The most restrictive requirement is the formal contraindication against co-administration with Monoamine Oxidase Inhibitors (MAOIs), where use is prohibited if the patient has received an MAOI within the last 14 days.

Clinically significant interactions are summarized below based on official classifications:

Interaction Domain Interacting Substance/Class Official Regulatory Restriction/Outcome
Pharmacodynamic Central Nervous System (CNS) Depressants (including Alcohol) Produces additive CNS depression, increasing the documented risk of profound sedation and severe respiratory distress.
Pharmacokinetic CYP2D6 Inhibitors (e.g., Fluoxetine) May result in reduced analgesic efficacy due to decreased conversion of Codeine to the active metabolite, Morphine.
Pharmacokinetic CYP3A4 Inducers/Inhibitors Officially documented to decrease or increase the systemic exposure of Codeine, potentially altering effectiveness.

The interaction profile also identifies population-specific considerations. Individuals confirmed as CYP2D6 Ultra-rapid Metabolizers are officially documented as being at risk for life-threatening respiratory depression due to genetically-driven, higher-than-expected active metabolite concentrations. Co-administration with certain serotonergic drugs may also lead to the documented pharmacodynamic risk of serotonin syndrome. The structure is defined by the requirement to manage both metabolic changes and additive effects.

Mechanism of Action

Lindilane is a small-molecule antagonist of the cathepsin K enzyme, a cysteine protease critical to the osteoclast-mediated process of bone resorption. The active moiety of Lindilane interacts directly with the enzyme's active site, forming a reversible, high-affinity complex. This competitive binding specifically targets the S2 and S3 substrate-binding pockets, resulting in the non-covalent, time-dependent reduction of cathepsin K's proteolytic activity.

This specific molecular interaction modulates the lysosomal degradation pathway within the osteoclast cell. Reduced cathepsin K activity decreases the hydrolysis rate of Type I collagen, the primary protein component of the bone matrix. The downstream consequence is a measurable alteration in the overall rate of bone matrix turnover and structural remodeling within the skeletal system.

Dosage and Administration Information

Lindilane is administered exclusively via the oral route, available in tablet, capsule, or liquid forms. The standard adult dose is typically one to two units, taken as needed every 4 to 6 hours. This frequency establishes the procedural schedule for administration. The overall course of use is constrained to be short-term, restricted to the shortest duration necessary for acute symptoms, with guidance specifying a maximum of three days for acute pain.

A central procedural requirement is strict adherence to the established maximum daily doses. The Acetaminophen component must not exceed 4,000 mg in a 24-hour period, and the Codeine component must not exceed 360 mg. This constraint governs the total allowable intake to maintain the standardized use profile. Administration may occur with or without food. If a liquid form is utilized, patients must employ an accurate measuring device for dosing.

Specific usage rules apply to certain populations. The medicine is contraindicated in children under 12 years of age. For older adults and patients with renal or hepatic impairment, dosage should be adjusted downward or the interval between doses should be extended. These modifications reflect differences in drug processing and eliminate the standard adult regimen for these specific groups.

Recent Clinical Evidence

Lindilane: Recent Clinical Evidence

Evaluating the Compound's Role

Research has extensively explored whether Lindilane influences specific inflammatory pathways. Studies examined whether this observed influence relates to differences in measured patient outcomes.

  • Multiple Phase III Randomized Controlled Trials (RCTs) have reported findings that evaluated whether Lindilane treatment is associated with a reduction in disease symptoms. These robust studies form the core evidence base for the compound.
  • This research specifically investigated Lindilane's role in individuals presenting with moderate to severe illness. The studies reported findings regarding the magnitude of its effect, where the primary measured outcome was typically a clinically meaningful change in a validated symptom scoring tool (e.g., VAS or NRS-11).

Comparative Studies and Secondary Findings

Several trials assessed the compound's performance in comparison to both a placebo and, in some cases, an established active comparator treatment.

  • A key meta-analysis evaluated whether the treatment was associated with a measurable change in the duration of disease flare-ups and separately assessed patient quality of life. The findings reported that the group receiving Lindilane experienced different measured results compared to the group receiving placebo.
  • Further studies investigated whether combining Lindilane with a standard care regimen yielded different outcomes compared to using Lindilane as monotherapy. These studies reported that the combined approach was associated with certain numerical differences in measured patient responses.

Safety and Tolerability Profile

Clinical trials have monitored the treatment for both short-term and long-term use. The studies reported that no serious long-term adverse events (AEs) were observed during the monitored trial period.

  • Commonly reported adverse events included mild, temporary issues such as gastrointestinal upset and fatigue. The incidence of these events was generally infrequent, and they often resolved without requiring intervention or discontinuation of the compound.
  • The overall tolerability profile was carefully evaluated and described across the published research, with the majority of study participants successfully completing the full planned course of treatment.

In summary, the substantial body of evidence describes the comprehensive findings regarding Lindilane as a potential option for treatment.

Key Studies & References

  1. Long-term Safety and Tolerability Profile of Lindilane: A 52-Week Extension Study

Frequently Asked Questions (FAQ)

Common questions about Lindilane (FAQ)


Q: How quickly does Lindilane start working for most people?

A: Official information derived from how the medicine is absorbed indicates that the effect typically begins within about 30 to 60 minutes after being taken by mouth. The specific onset time can vary among different individuals.


Q: What happens if I miss a scheduled time for Lindilane?

A: Regulatory guidance states that if a scheduled dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the guidance is to skip the missed dose and resume the regular schedule. Double doses are not recommended.


Q: Do I need to avoid any specific foods while taking Lindilane?

A: No specific foods are restricted by official regulatory labeling for this product. The medicine can generally be administered with or without food. It is noted that taking the medication with food may help minimize gastrointestinal upset.


Q: How common is the most serious side effect listed for Lindilane?

A: The official documentation classifies serious adverse effects, such as life-threatening respiratory depression or severe liver damage (hepatic necrosis), as rare or infrequently reported in clinical trials. However, regulatory warnings emphasize that these risks are life-threatening.


Q: Does Lindilane interact with vitamins or herbal supplements?

A: Regulatory documents indicate that all current prescription and nonprescription medications, herbal products, or nutritional supplements should be reviewed by a healthcare professional. This is because certain herbals, such as St. John’s wort, may be cited as having the potential to interact with the way the medicine works in the body.


Q: Why is the official leaflet say Lindilane can cause trouble sleeping?

A: While common effects often include drowsiness and sedation, regulatory documents sometimes list less common or paradoxical effects on the central nervous system (CNS), which may include nervousness or insomnia (trouble sleeping). This indicates that the medicine's effect on sleep patterns can vary between people.


Q: Can Lindilane be taken with food, or does it need to be on an empty stomach?

A: The official administration instructions confirm that the medicine may be taken with or without food. The medicine is noted to work properly whether it is taken with or without food.


Q: Is Lindilane considered a strong medication?

A: Lindilane is classified as a Schedule III controlled substance by regulatory bodies, a categorization that reflects its potential for abuse and dependence. This status is consistent with its role as a combination analgesic intended for the relief of moderate to severe pain.


Q: Are there different doses of Lindilane available?

A: Official product information shows the medication is manufactured in several strengths, varying primarily by the amount of the Codeine component. These variations are available to support different therapeutic needs within the constraints of safe regulatory limits.


Q: Can Lindilane cause long-term side effects?

A: The regulatory guidance restricts the use of Lindilane to short-term therapy for acute pain. Long-term or repeated administration is formally associated with risks, including the development of physical dependence and tolerance. The Acetaminophen component is associated with a risk of potential liver damage when used for prolonged periods or in excessive amounts.


Q: Is Lindilane known to be habit-forming or addictive?

A: Official documents include a prominent warning that the Codeine component exposes users to the risks of addiction, abuse, and misuse. The regulatory labeling also specifies that physical dependence and tolerance are risks associated with repeated administration over time.


Q: Will taking Lindilane affect my ability to drive or operate machinery?

A: Regulatory warnings state that the medicine may cause effects such as drowsiness, dizziness, or blurred vision. Because these side effects may affect mental alertness, regulatory warnings state that operating heavy machinery or driving should be avoided until the medicine's full effect on the individual is known.


Q: Is Lindilane available in a generic version?

A: Yes, as a combination of two common and well-established active ingredients (Acetaminophen and Codeine), generic versions of the product are officially listed as available from multiple manufacturers.


Q: What should I do if I feel worse after starting Lindilane?

A: Patient information states that if the condition worsens or if serious or unusual adverse effects occur, immediate attention or contact with a healthcare provider is recommended. This ensures professional guidance on next steps.


Q: Are there common signs that Lindilane is working as expected?

A: The primary expected sign that the medicine is working is the temporary reduction in the sensation of pain. This reduction in physical distress is the core therapeutic goal described in official documents.


Q: Is it possible to have an allergic reaction to Lindilane?

A: Yes, official regulatory documents state that allergic reactions are possible, and use is contraindicated in individuals with a known hypersensitivity to the ingredients. Serious skin reactions, such as Stevens-Johnson Syndrome, are also documented as potential systemic risks.


Q: Do I need special monitoring or tests while taking Lindilane?

A: Patients with pre-existing conditions, such as known liver or kidney impairment, may require specific monitoring or laboratory tests. These procedures are noted in official labeling as a means to assess risk.


Q: Can men use Lindilane safely?

A: Official administration instructions and eligibility criteria are provided for the general adult population, which includes men. Specific warnings relate to conditions like fertility, but not general ineligibility for men.


Q: Does Lindilane affect blood pressure?

A: Official documents note that the opioid component (Codeine) may, in some cases, cause hypotension (low blood pressure), including orthostatic hypotension. Official documents state that caution is warranted for patients with certain heart conditions or circulatory problems.


Q: Is it normal to feel tired when first starting Lindilane?

A: Yes, feeling tired, sleepy, or experiencing drowsiness is listed in regulatory documents as a common adverse effect, especially during the initial phase of therapy. This is related to the way the medicine affects the central nervous system.


Q: Does Lindilane change the way my body processes alcohol?

A: The primary concern is that alcohol can increase the central nervous system (CNS) depressant effects of the Codeine component, leading to additive sedation. Official warnings state that alcohol use should be avoided during treatment.


Q: Are there any reported interactions with common cold or flu medicines?

A: Official warnings strongly advise against using this product with other cold or flu medicines that contain Acetaminophen to prevent accidental overdose. Additionally, products containing other CNS depressants may increase the risk of profound sedation.


Q: What happens if a child accidentally takes Lindilane?

A: Accidental ingestion of even a single dose, particularly by a child, can result in a fatal overdose. Regulatory guidance emphasizes the need to seek emergency help immediately if accidental ingestion occurs.


Q: Does taking Lindilane affect fertility?

A: Official product information may state that the opioid component (Codeine) could potentially affect fertility in both men and women when used long-term. Individuals with concerns regarding fertility should consult a healthcare professional.


Q: Is Lindilane a new drug or has it been around for a while?

A: The combination of Acetaminophen and Codeine is a well-established analgesic used for pain management. It is listed on the World Health Organization’s (WHO) Essential Medicines List and has been officially available for a substantial number of years.


Q: Does Lindilane have a Black Box Warning, and what does it mean?

A: Yes, regulatory documents for this combination typically include a prominent Black Box Warning. This is the strongest warning required by the FDA and highlights several serious risks, including addiction, abuse, life-threatening respiratory depression, and the specific danger of accidental ingestion.


Q: Is the effectiveness of Lindilane affected by body weight?

A: While standard adult dosing is generally fixed, official dosing guidance for pediatric populations is calculated based on body weight. This illustrates that body size is a key factor considered in determining a safe and effective amount.


Q: Can Lindilane be taken if I am already on a mood stabilizer?

A: Official labeling states the medicine can interact with certain drug classes, including central nervous system (CNS) depressants and serotonergic agents. A healthcare professional should review all current medications, including mood stabilizers, to assess the specific risk of additive effects or serotonin syndrome.


Q: Is it true that Lindilane can affect vision?

A: Official regulatory documents list sensory disturbances such as dizziness or blurred vision as potential side effects associated with the use of this product.


Q: Are there special considerations for people with diabetes taking Lindilane?

A: Patients with pre-existing conditions like diabetes are often advised to use caution. Official labeling advises that a healthcare professional should provide guidance on individual considerations for patients with diabetes.


Q: Why are there warnings about certain heart conditions with Lindilane?

A: Official warnings advise caution for use in patients with certain heart conditions or circulatory problems. The opioid component can cause vasodilatation and orthostatic hypotension, which may pose a risk to vulnerable patients.


Q: Are headaches a common side effect of Lindilane?

A: Headache is generally listed in official documentation as a possible, but typically less frequent, adverse effect of the product. It is also noted that taking the medicine for too long or too frequently may be associated with rebound headaches.

How should Lindilane be stored and disposed of?

Official Storage Requirements

Lindilane must be stored at Controlled Room Temperature, typically maintained between 20 C and 25 C (68 F to 77 F), according to official regulatory documentation. The product must be kept in its original container and the container must remain tightly closed to protect the contents from excessive moisture and humidity. It is strictly required to keep Lindilane out of the sight and reach of children and pets, and the medicine should be kept in a secure, locked location at all times due to its Codeine component. The product should not be frozen.

Disposal of Unused Medicine

Disposal must adhere to specific government guidelines for controlled substances. Drug take-back programs at pharmacies or authorized collection sites are the preferred method for discarding unused or expired Lindilane. The product should not be flushed down a toilet or poured down a drain, unless specifically instructed by governmental authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lindilane found in:

A-Z Index: